GPCR Agonist-to-Antagonist Conversion: Enabling the Design of Nucleoside Functional Switches for the A2A Adenosine Receptor

Modulators of the G protein-coupled A2A adenosine receptor (A2AAR) have been considered promising agents to treat Parkinson’s disease, inflammation, cancer, and central nervous system disorders. Herein, we demonstrate that a thiophene modification at the C8 position in the common adenine scaffold converted an A2AAR agonist into an antagonist. We synthesized and characterized a novel A2AAR antagonist, 2 (LJ-4517), with Ki = 18.3 nM. X-ray crystallographic structures of 2 in complex with two thermostabilized A2AAR constructs were solved at 2.05 and 2.80 Å resolutions. In contrast to A2AAR agonists, which simultaneously interact with both Ser2777.42 and His2787.43, 2 only transiently contacts His2787.43, which can be direct or water-mediated. The n-hexynyl group of 2 extends into an A2AAR exosite. Structural analysis revealed that the introduced thiophene modification restricted receptor conformational rearrangements required for subsequent activation. This approach can expand the repertoire of adenosine receptor antagonists that can be designed based on available agonist scaffolds.

[1]  K. Jacobson,et al.  Subtle Chemical Changes Cross the Boundary between Agonist and Antagonist: New A3 Adenosine Receptor Homology Models and Structural Network Analysis Can Predict This Boundary. , 2021, Journal of Medicinal Chemistry.

[2]  Jianyi Wang,et al.  Advance of structural modification of nucleosides scaffold , 2021, European Journal of Medicinal Chemistry.

[3]  James D. Clarke,et al.  Small molecule AZD4635 inhibitor of A2AR signaling rescues immune cell function including CD103+ dendritic cells enhancing anti-tumor immunity , 2020, Journal for ImmunoTherapy of Cancer.

[4]  Yoonji Lee,et al.  Importance of protein dynamics in the structure-based drug discovery of class A G protein-coupled receptors (GPCRs). , 2019, Current opinion in structural biology.

[5]  Pier Andrea Borea,et al.  Pharmacology of Adenosine Receptors: The State of the Art. , 2018, Physiological reviews.

[6]  K. Jacobson,et al.  A3 Adenosine Receptors as Modulators of Inflammation: From Medicinal Chemistry to Therapy , 2018, Medicinal research reviews.

[7]  Sun Choi,et al.  Recent Advances in Structure-Based Drug Design Targeting Class A G Protein-Coupled Receptors Utilizing Crystal Structures and Computational Simulations. , 2018, Journal of medicinal chemistry.

[8]  David E. Gloriam,et al.  Structural Mapping of Adenosine Receptor Mutations: Ligand Binding and Signaling Mechanisms. , 2018, Trends in pharmacological sciences.

[9]  Andrew S Doré,et al.  Towards high throughput GPCR crystallography: In Meso soaking of Adenosine A2A Receptor crystals , 2018, Scientific Reports.

[10]  K. Varani,et al.  Inhibition of A2A Adenosine Receptor Signaling in Cancer Cells Proliferation by the Novel Antagonist TP455 , 2017, Front. Pharmacol..

[11]  E. Segala,et al.  Structures of Human A1 and A2A Adenosine Receptors with Xanthines Reveal Determinants of Selectivity. , 2017, Structure.

[12]  T. Ceska,et al.  Crystal structure of the adenosine A2A receptor bound to an antagonist reveals a potential allosteric pocket , 2017, Proceedings of the National Academy of Sciences.

[13]  Berk Hess,et al.  GROMACS: High performance molecular simulations through multi-level parallelism from laptops to supercomputers , 2015 .

[14]  J. Powell,et al.  A2aR antagonists: Next generation checkpoint blockade for cancer immunotherapy , 2015, Computational and structural biotechnology journal.

[15]  Sunhwan Jo,et al.  CHARMM‐GUI Membrane Builder toward realistic biological membrane simulations , 2014, J. Comput. Chem..

[16]  Manuel de Lera Ruiz,et al.  Adenosine A2A receptor as a drug discovery target. , 2014, Journal of medicinal chemistry.

[17]  Jing Huang,et al.  CHARMM36 all‐atom additive protein force field: Validation based on comparison to NMR data , 2013, J. Comput. Chem..

[18]  Alexander D. MacKerell,et al.  Automation of the CHARMM General Force Field (CGenFF) I: Bond Perception and Atom Typing , 2012, J. Chem. Inf. Model..

[19]  R. Stevens,et al.  Structural Basis for Allosteric Regulation of GPCRs by Sodium Ions , 2012, Science.

[20]  K. Jacobson,et al.  Structure-activity relationships of truncated C2- or C8-substituted adenosine derivatives as dual acting A₂A and A₃ adenosine receptor ligands. , 2012, Journal of medicinal chemistry.

[21]  Nathan Robertson,et al.  Biophysical Mapping of the Adenosine A2A Receptor , 2011, Journal of medicinal chemistry.

[22]  A. Leslie,et al.  Agonist-bound adenosine A2A receptor structures reveal common features of GPCR activation , 2011, Nature.

[23]  R. Stevens,et al.  Structure of an Agonist-Bound Human A2A Adenosine Receptor , 2011, Science.

[24]  M. Legraverend,et al.  Regioselective Sonogashira cross-coupling reactions of 6-chloro-2,8-diiodo-9-THP-9H-purine with alkyne derivatives , 2011 .

[25]  R. Stevens,et al.  Rastering strategy for screening and centring of microcrystal samples of human membrane proteins with a sub-10 µm size X-ray synchrotron beam , 2009, Journal of The Royal Society Interface.

[26]  Sang Kook Lee,et al.  Structure-activity relationships of truncated adenosine derivatives as highly potent and selective human A3 adenosine receptor antagonists. , 2009, Bioorganic & medicinal chemistry.

[27]  Dharini van der Hoeven,et al.  Characterization of the A2B Adenosine Receptor from Mouse, Rabbit, and Dog , 2009, Journal of Pharmacology and Experimental Therapeutics.

[28]  V. Cherezov,et al.  Crystallizing membrane proteins using lipidic mesophases , 2009, Nature Protocols.

[29]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[30]  Taehoon Kim,et al.  CHARMM‐GUI: A web‐based graphical user interface for CHARMM , 2008, J. Comput. Chem..

[31]  E. Benarroch.  Adenosine and its receptors , 2008, Neurology.

[32]  C. Nájera,et al.  The Sonogashira reaction: a booming methodology in synthetic organic chemistry. , 2007, Chemical reviews.

[33]  K. Fuxe,et al.  Targeting adenosine A2A receptors in Parkinson's disease , 2006, Trends in Neurosciences.

[34]  G. Piccialli,et al.  Studies toward the synthesis of pinolidoxin, a phytotoxic nonenolide from the fungus Ascochyta pinodes. Determination of the configuration at the C-7, C-8, and C-9 chiral centers and stereoselective synthesis of the C(6)-C(18) fragment. , 2000, The Journal of organic chemistry.

[35]  John K. Stille,et al.  The Palladium‐Catalyzed Cross‐Coupling Reactions of Organotin Reagents with Organic Electrophiles [New Synthetic Methods (58)] , 1986 .

[36]  Y. Cheng,et al.  Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction. , 1973, Biochemical pharmacology.